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Src is one the best studied proto-oncogene. 10 potential lead molecules had shown 
good pharmacokinetic, among them lead ‘1’ (fiestin) with least XP G score -11.56 
was identified as best lead molecule certainly aid the experimental designing for 
treatment of chronic prostate cancer in lesser time if synthesized and tested. 
Figure 3. Proposed  ten lead molecules  
Figure 1. Src plays a key role in motility, proliferation and   
survival 
Figure 4. Docking complex of human Src kinase with lead 1 molecule 
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Graph 1. Graph showing docking score and ligand efficiency of the ten 
lead molecules 
· Src (pronounced "sarc" as it is short for sarcoma), is the first oncogene and the first non receptor tyrosine kinase, origi-
nally discovered by J. Michael Bishop and Harold E. Varmus, for which they won the 1989 Nobel Prize in Physiology 
and Medicine.  
· It plays a key role in cell morphology, motility, proliferation and survival. 
· Src signaling is involved in androgen-induced proliferation of prostate cancer. Over expression of Src kinase 
   activity leads to prostate cancer. Bone metastasis occurs in the majority of patients with prostate cancer during  
    advanced stages of the disease. 
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Introduction 
Figure 2.  Crystal structure of human Src  kinase 
No of hydrogen bond donars, Ro-
tatable bonds, log p value less than 5, 
No of hydrogen bonds acceptors less 
than 10 and Molecular weight less 
then 500. 
Schrodinger software 
suite 9.0 
Asinex ltd, Chem PDB, KEGG, 
Chem bank, Not annotated NCI, 
Anti HIV, Drug likeness & Akos 
Three published human Src 
kinase inhibitors 
Results and discussion 
Showing Ten Lead 
molecule  docking 
score and ligand effi-
ciency, amoung them 
lead 1molecule have 
have XPG score   
11.56  kcal/mol  and  
ligand efficiency of  
–12.68 
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